Provided By GlobeNewswire
Last update: Aug 13, 2024
FOSTER CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today positive preliminary clinical data for the cohort of patients with non-CNS MET fusion solid tumors from the Phase 2 SPARTA trial of vebreltinib.
NASDAQ:APLMW (8/5/2025, 8:00:00 PM)
0.0227
+0 (+3.18%)
NASDAQ:APLM (8/5/2025, 8:00:00 PM)
5.72
+0.17 (+2.97%)
Find more stocks in the Stock Screener